Search Results - robert+mckenna

2 Results Sort By:
Recombinant AAV9 Vectors with Modified Capsids for Escaping Neutralizing Human Antibodies
Amino Acid Substitutions on the Capsid Surface to Evade Neutralizing Antibodies and Improve Gene Therapy Efficacy and Safety Adeno-associated virus (AAV)-based vectors are the leading platform for the delivery of gene therapy in vivo, but have a limitation in that they need to avoid neutralizing and potentially dangerous immune response to the AAV...
Published: 9/4/2024   |   Inventor(s): Robert McKenna, Mario Mietzsch, Jane Hsi, Austin Nelson
Keywords(s):  
Category(s): Technology Classifications > Human Health Care > Gene Therapy, Technology Classifications > Human Health Care > Therapeutics
AAV Vectors for Improved CNS Targeting
Targets Neuronal Cells to Develop Gene Therapies and Treat Neurological Diseases These engineered AAV vectors are designed to target neuronal cell types to aid in the development of gene therapies, which can treat a variety of neurological diseases. In 2020, the market for CNS targeting technologies was worth $6 billion and is expected to reach $46.5...
Published: 7/14/2023   |   Inventor(s): Robert McKenna, Mario Mietzsch, Judit Penzes, Mavis Agbandje-McKenna, Chun Yu, Alberto Ybargollin, Alana Johnson, Jane Hsi
Keywords(s):  
Category(s): Technology Classifications > Human Health Care > Therapeutics